137 related articles for article (PubMed ID: 35689555)
1. Peptic Ulcer Disease and Risk of Hip Fracture: A General Population-based Cohort Study.
Li J; Lu N; Lyu H; Lei G; Zeng C; Wei J; Wang Y; Xie D
J Clin Endocrinol Metab; 2022 Aug; 107(9):e3738-e3746. PubMed ID: 35689555
[TBL] [Abstract][Full Text] [Related]
2. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
3. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
[TBL] [Abstract][Full Text] [Related]
4. Increased Risk of Osteoporosis in Patients With Peptic Ulcer Disease: A Nationwide Population-Based Study.
Wu CH; Tung YC; Chai CY; Lu YY; Su YF; Tsai TH; Kuo KL; Lin CL
Medicine (Baltimore); 2016 Apr; 95(16):e3309. PubMed ID: 27100415
[TBL] [Abstract][Full Text] [Related]
5. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis.
Chen CH; Lin CL; Kao CH
Osteoporos Int; 2016 Jun; 27(6):2117-26. PubMed ID: 26860609
[TBL] [Abstract][Full Text] [Related]
6. Long-term proton pump inhibitor therapy and risk of hip fracture.
Yang YX; Lewis JD; Epstein S; Metz DC
JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
8. Seborrheic dermatitis and risk of incident peptic ulcer disease: A nationwide population-based cohort study.
Chen TL; Lin MC; Wang JH; Lin CS; Hsu CY; Loh CH
Australas J Dermatol; 2021 Nov; 62(4):e546-e553. PubMed ID: 34370301
[TBL] [Abstract][Full Text] [Related]
9. Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model.
Park DH; Seo SI; Lee KJ; Kim J; Kim Y; Seo WW; Lee HS; Shin WG; Yoo JJ
J Gastroenterol Hepatol; 2022 Aug; 37(8):1534-1543. PubMed ID: 35501296
[TBL] [Abstract][Full Text] [Related]
10. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.
Khalili H; Huang ES; Jacobson BC; Camargo CA; Feskanich D; Chan AT
BMJ; 2012 Jan; 344():e372. PubMed ID: 22294756
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes.
Chou YS; Jiang HJ; Chen CH; Ho PS; Lee TC
Sci Rep; 2020 Aug; 10(1):14081. PubMed ID: 32826941
[TBL] [Abstract][Full Text] [Related]
12. Risk of uncomplicated peptic ulcer disease in a cohort of new users of low-dose acetylsalicylic acid for secondary prevention of cardiovascular events.
Ruigómez A; Johansson S; Nagy P; Martín-Pérez M; Rodríguez LA
BMC Gastroenterol; 2014 Dec; 14():205. PubMed ID: 25492031
[TBL] [Abstract][Full Text] [Related]
13. Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis.
González-Pérez A; Sáez ME; Johansson S; Nagy P; García Rodríguez LA
PLoS One; 2014; 9(7):e101768. PubMed ID: 25003908
[TBL] [Abstract][Full Text] [Related]
14. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
[TBL] [Abstract][Full Text] [Related]
15. Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole.
Tang RS; Wu JC
Clin Interv Aging; 2013; 8():1433-43. PubMed ID: 24187492
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitor use and the risk of fractures among an older adult cohort.
Harding BN; Weiss NS; Walker RL; Larson EB; Dublin S
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):596-603. PubMed ID: 29493043
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study.
Min YW; Lee YC; Kim K; Ryu S; Hong KS; Jeon HH; Kim YS; Park JH; Son HJ; Rhee PL
Korean J Intern Med; 2020 Sep; 35(5):1084-1093. PubMed ID: 31671930
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of osteoporosis in patients with peptic ulcer: a follow-up study using a national sample cohort.
Choi HG; Rhim CC; Yoon JY; Park BJ; Min CY; Lee SW
Arch Osteoporos; 2019 Oct; 14(1):105. PubMed ID: 31659478
[TBL] [Abstract][Full Text] [Related]
20. Peptic ulcer disease risk in chronic kidney disease: ten-year incidence, ulcer location, and ulcerogenic effect of medications.
Liang CC; Muo CH; Wang IK; Chang CT; Chou CY; Liu JH; Yen TH; Huang CC; Chung CJ
PLoS One; 2014; 9(2):e87952. PubMed ID: 24498412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
